Post Hoc parkinson's disease: Identifying an uncommon disease in the cardiovascular health study

Neuroepidemiology

Volumn 35, Issue 4, 2010, Pages 241-249

  Ton, T G ^a   Jain, S ^c   Boudreau, R ^d   Thacker, E L ^b   Strotmeyer, E S ^d   Newman, A B ^d   Longstreth, W T ^a,b   Checkoway, H ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular Health Study; Cohort study; Epidemiology; International Classification of Diseases, 9th edition; Parkinson's disease; Smoking

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BIPERIDEN; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; PROCYCLIDINE; PROFENAMINE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

AGED; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOTHESIS; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PARKINSON DISEASE; PROSPECTIVE STUDY; RISK ASSESSMENT; SELF REPORT; SMOKING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR SYSTEM; COHORT STUDIES; FEMALE; HEALTH STATUS; HUMANS; INCIDENCE; MALE; ODDS RATIO; PARKINSON DISEASE; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SMOKING; UNITED STATES;

EID: 77957162937     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319895     Document Type: Article

References (21)

1. Gandhi S, Wood NW: Genome-wide asso-ciation studies: the key to unlocking neuro-degeneration? Nat Neurosci 2010; 13: 789-794.
2. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ: A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-284.
3. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-276.
4. Swarztrauber K, Anau J, Peters D: Identify-ing and distinguishing cases of parkinson-ism and Parkinson's disease using ICD-9 CM codes and pharmacy data. Mov Disord 2005; 20: 964-970.
5. Hook EB, Regal RR: Capture-recapture methods in epidemiology: methods and lim-itations. Epidemiol Rev 1995; 17:243-264.
6. Bild DE, Fitzpatrick A, Fried LP, Wong ND, Haan MN, Lyles M, Bovill E, Polak JF, Schulz R: Age-related trends in cardiovascular mor-bidity and physical functioning in the elder-ly: the Cardiovascular Health Study. J Am Geriatr Soc 1993; 41:1047-1056.
7. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR: Epidemiologic observations on Parkinson's disease: inci-dence and mortality in a prospective study of middle-aged men. Neurology 1996; 46:1044-1050.
8. Anderson DW, Rocca WA, de Rijk MC, Grigoletto F, Melcon MO, Breteler MM, Maraganore DM: Case ascertainment un-certainties in prevalence surveys of Parkin-son's disease. Mov Disord 1998; 13: 626-632.
9. De Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hof-man A: Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995; 45:2143-2146.
10. Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, Widner H, Lew MF, Welsh M, Pedersen NL: Complete ascer-tainment of Parkinson disease in the Swed-ish twin registry. Neurobiol Aging 2008; 29: 1765-1773.
11. Von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R: Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15:473-490.
12. Mayeux R, Denaro J, Hemenegildo N, Mard-er K, Tang MX, Cote LJ, Stern Y: A popula-tion-based investigation of Parkinson's dis-ease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49:492-497.
13. Aminoff MJ: Treatment should not be initi-ated too soon in Parkinson's disease. Ann Neurol 2006; 59: 562-564, discussion 564-565.
14. Schapira AH, Obeso J: Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
15. Lang A: When and how should treatment be started in Parkinson's disease? Neurology 2009; 72:S39-S43.
16. Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Incidence and distribution of parkinsonism in Olmsted County, Minne-sota, 1976-1990. Neurology 1999; 52:1214-1220.
17. Koepsell TD, Weiss NS: Epidemiologic Methods: Studying the Occurrence of Ill-ness. New York, Oxford University Press, 2003.
18. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strick-land D, Van Den Eeden SK, Gorell J: Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007; 64: 990-997.
19. Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 2009; 169: 1064-1069.
20. Kamel F, Tanner C, Umbach D, Hoppin J, Alavanja M, Blair A, Comyns K, Goldman S, Korell M, Langston J, Ross G, Sandler D: Pes-ticide exposure and self-reported Parkin-son's disease in the Agricultural Health Study. Am J Epidemiol 2007; 165:364-374.
21. Hu G, Jousilahti P, Bidel S, Antikainen R, Tu-omilehto J: Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007; 30: 842-847.